Neuron Biopharma, S.A. filed its Annual on Apr 24, 2014 for the period ending Dec 31, 2013. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -.--% | -.--% |
2017 | Neuron BioLabs, S.L. cancelled the acquisition of diagnostics operations, R&D services and patents of Alzheimer's disease from Neuron Bio, SA. | CI |
2017 | Neol Biosolutions Seeks Investors | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 51.94L | |
+10.13% | 11TCr | |
+12.83% | 11TCr | |
-5.39% | 2.22TCr | |
-0.67% | 2.13TCr | |
-4.64% | 1.88TCr | |
-6.32% | 1.75TCr | |
-39.36% | 1.72TCr | |
+6.46% | 1.41TCr | |
+35.06% | 1.22TCr |
- Stock Market
- Equities
- NEU Stock
- News Neuron Bio, S.A.
- Neuron Biopharma, S.A. Auditor Raises 'Going Concern' Doubt